로딩 중...
52주 최고가 대비 73.3% 위치
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $14.95B | $15.44B | $15.46B | $15.12B |
| 영업이익 | - | $2.69B | $2.49B | $2.63B | $2.71B |
| 당기순이익 | - | $2.06B | $1.66B | $1.03B | $1.47B |
| 잉여현금흐름 (FCF) | - | $2.15B | $2.70B | $1.33B | $1.72B |
| 수익성 비율 | |||||
| 영업이익률 | - | 18.0% | 16.1% | 17.0% | 18.0% |
| 순이익률 | - | 13.8% | 10.8% | 6.7% | 9.7% |
| ROE (자기자본이익률) | - | 10.3% | 14.8% | 10.7% | 13.7% |
| ROA (자산이익률) | - | 7.6% | 6.0% | 4.0% | 5.4% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 3.3% | 0.1% | -2.1% |
| EPS 성장률 (YoY) | - | - | -17.6% | -40.0% | 40.7% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | 20.8x | 37.0x | 22.4x |
| PBR (주가순자산배수) | - | - | 3.2x | 4.0x | 3.0x |
| PSR (주가매출배수) | - | - | 2.3x | 2.5x | 2.2x |
| FCF Yield | - | - | 7.5% | 3.5% | 5.3% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.01 | 0.75 | 0.90 | 0.81 |
| 유동비율 | - | 1.50 | 1.12 | 0.96 | 0.96 |
KRAFT HEINZ CO/THE
$23.33
$27.7B